Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Sublingual apomorphine and Parkinson's disease.

Literature DB >> 2614447

Sublingual apomorphine and Parkinson's disease.

A J Lees, J L Montastruc, N Turjanski, O Rascol, B Kleedorfer, H Peyro Saint-Paul, G M Stern, A Rascol.

Abstract

Entities: Chemical Disease

Mesh：

Substances：
Apomorphine

Year: 1989 PMID： 2614447 PMCID： PMC1031611 DOI： 10.1136/jnnp.52.12.1440

Source DB: PubMed Journal: J Neurol Neurosurg Psychiatry ISSN： 0022-3050 Impact factor: 10.154

× No keyword cloud information.

4 in total

1. Subcutaneous apomorphine in Parkinson's disease.

Authors: P Pollak; A S Champay; M Hommel; J E Perret; A L Benabid
Journal: J Neurol Neurosurg Psychiatry Date: 1989-04 Impact factor: 10.154

2. Subcutaneous apomorphine in parkinsonian on-off oscillations.

Authors: C M Stibe; A J Lees; P A Kempster; G M Stern
Journal: Lancet Date: 1988-02-20 Impact factor: 79.321

3. Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.

Authors: G C Cotzias; P S Papavasiliou; E S Tolosa; J S Mendez; M Bell-Midura
Journal: N Engl J Med Date: 1976-03-11 Impact factor: 91.245

4. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.

Authors: P A Kempster; J P Frankel; M Bovingdon; R Webster; A J Lees; G M Stern
Journal: J Neurol Neurosurg Psychiatry Date: 1989-06 Impact factor: 10.154

4 in total

12 in total

Review 1. Pharmacological treatment of Parkinson's disease.

Authors: A Münchau; K P Bhatia
Journal: Postgrad Med J Date: 2000-10 Impact factor: 2.401

2. Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease.

Authors: F Durif; E Jeanneau; F Serre-Debeauvais; D Deffond; A Eschalier; M Tournilhac
Journal: Eur J Clin Pharmacol Date: 1991 Impact factor: 2.953

Sublingual apomorphine and Parkinson's disease.

1. Subcutaneous apomorphine in Parkinson's disease.

2. Subcutaneous apomorphine in parkinsonian on-off oscillations.

3. Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.

4. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.

Review 1. Pharmacological treatment of Parkinson's disease.

2. Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease.

Review 3. Old Drugs, New Delivery Systems in Parkinson's Disease.

Review 4. [Apomorphine in the treatment of Parkinson's Disease].

5. Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease.

Review 6. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Review 7. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.

Review 8. Current status of dopamine agonists in Parkinson's disease management.

9. Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.

Review 10. Clinical pharmacology of dopamine agonists in Parkinson's disease.